Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01971099

Enrollment

Registered

2013-10-29

Start date

2013-05-31

Completion date

2015-09-30

Last updated

2016-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoactive Sexual Desire Disfunction

Keywords

sexual function, hypoactive, desire, androgens

Brief summary

Hypoactive Sexual Desire Disorder (HSDD) is the most prevalent female sexual dysfunction in society and is strongly linked to the quality of life of women. The androgen hormones decline over age in the premenopausal period, which occurs around 20 years. Tribulus terrestris is a plant native to India, recommended in the treatment of infertility, low libido and impotence. Its main active ingredient is the protodioscin, which has been attributed to an increase in testosterone levels and improved sexual function. The aim of this study is to evaluate the effects of Tribulus Terrestris in premenopausal women with HSDD.

Interventions

DRUGtribulus terrestris

patients will use 750mg/day of tribulus terrestris

OTHERPlacebo

patients will take one pill a day (the same shape of the drug)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* regular menstrual cycle * with no use of hormonal contraception within the last 3 months * without any medication, drugs or alcohol. * Healthy patients without systemic or psychiatric disease

Exclusion criteria

* Patients with amenorrhea and/or pregnant. * Patients who underwent bilateral oophorectomy. * Patient smoker (10 cigarettes per day). * Patients with blood pressure \> 160/90 mm Hg. * Patient with breast or endometrial carcinoma. * Patients with a history of myocardial infarction. * Patient with Diabetes. * Patient with vaginal bleeding from any source. * Patients with hepatic injury. * Patients with active thrombophlebitis or thromboembolic disorders recent * Patients with interpersonal relationship problems with your relationship or partner * Patients with sexual problems from your partner

Design outcomes

Primary

Measure	Time frame	Description
Sexual Desire	120 days	we will use the Quotient Sexual - Version Feminine (QS-F) brazilian questionary to make the evaluation

Secondary

Measure	Time frame	Description
serum levels of prolactin and thyroid-stimulating hormone (TSH)	120 days	blood test

Other

Measure	Time frame	Description
serum levels of testosterone and sex hormone-binding globulin (SHBG)	120 days	blood test

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026